HETEROCYCLIC COMPOUNDS AND USES THEREOF

1 . A compound of Formula (A″):

wherein:

R 1 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —COR 2 , —COOR 3 , or —CONR 4 R 5 ;

z is 0, 1, 2, or 3;

each instance of R 3a is independently hydrogen, alkyl, alkenyl, alkynyl, alkoxyl, halogen, cyano, amino, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

B is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —COR 2 , —COOR 3 , —CONR 4 R 5 , or —Si(R 6 ) 3 ;

wherein R 2 , R 3 , R 4 , R 5 , and R 6 are each, independently, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

R 1c is hydrogen, alkyl, alkenyl, or alkynyl;

R 2c is hydrogen, alkyl, alkenyl, or alkynyl;

W d is heteroaryl, cycloalkyl, heterocycloalkyl, or aryl; and

X is CR 1a or N;

wherein R 1a is hydrogen, halo, alkyl, alkenyl, alkynyl, or CN;

wherein each alkyl, alkenyl, or alkynyl is optionally substituted with one or more halo, OH, alkoxy, NH 2 , NH(alkyl), N(alkyl) 2 , COH, CO(alkyl), COOH, COO(alkyl), CONH 2 , CONH(alkyl), CON(alkyl) 2 , S(O)(alkyl), S(O) 2 (alkyl), cycloalkyl, heterocycloalkyl, aryl or heteroaryl;

wherein each cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally substituted with one or more halo, alkyl, alkenyl, alkynyl, OH, alkoxy, oxo, NH 2 , NH(alkyl), N(alkyl) 2 , COH, CO(alkyl), COOH, COO(alkyl), CONH 2 , CONH(alkyl), CON(alkyl) 2 , S(O)(alkyl), or S(O) 2 (alkyl);

wherein in Formula (A″), when X is CH, B is unsubstituted phenyl, and W d is

then R 1 is not phenyl;

or a pharmaceutically acceptable form thereof.

2 . The compound of claim 1 , wherein the compound is a compound of Formula (A′):

or a pharmaceutically acceptable form thereof.

3 . The compound of claim 2 , wherein the compound is a compound of Formula (A):

or a pharmaceutically acceptable form thereof.

4 - 35 . (canceled)

36 . A compound in Table 3, Table 4, Table 5, Table 6, Table 7, Table 8, Table 9, Table 10, Table 11, Table 12, Table 13, or Table 14, or a pharmaceutically acceptable form thereof.

37 . A pharmaceutical composition comprising a compound of claim 1 , and a pharmaceutically acceptable excipient, diluent, or carrier.

38 . A method of inhibiting a PI3 kinase, comprising contacting the PI3 kinase with an effective amount of a compound of claim 1 .

39 - 40 . (canceled)

41 . A method of treating or preventing a PI3K mediated disorder in a subject, comprising administering a therapeutically effective amount of a compound of claim 1 to said subject.

42 - 46 . (canceled)

47 . A process for preparing Compound 4 of the formula:

comprising reacting Compound B of the formula:

with an alkyne of the formula:

48 . The process of claim 47 , wherein the reaction between Compound B and the alkyne occurs in the presence of dichlorobis(acetonitrile)palladium, X-Phos, and cesium carbonate.

49 . The process of claim 47 , wherein the reaction between Compound B and the alkyne occurs in a solvent of propionitrile.

50 . The process of claim 47 , wherein the reaction between Compound B and the alkyne occurs at 85° C.

51 . The process of claim 47 , wherein Compound B is prepared by a process comprising reacting Compound A of the formula:

with a carboxylic acid of the formula:

52 . The process of claim 51 , wherein the reaction between Compound A and the carboxylic acid occurs in the presence of HOBt hydrate, EDC, and Hunig's base.

53 . The process of claim 51 , wherein the reaction between Compound A and the carboxylic acid occurs in a solvent of N,N-dimethylformamide.

54 . The process of claim 51 , wherein the reaction between Compound A and the carboxylic acid occurs at room temperature.